Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Enliven Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Enliven Therapeutics, Inc. has 6 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Enliven Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Enliven Therapeutics, Inc.. Customers appear here when Enliven Therapeutics, Inc. names them, or when a company names Enliven Therapeutics, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“The drug product for the ELVN-001 program is manufactured at Latitude Pharmaceuticals Inc., Quotient Sciences, and CoreRx.”
FILING10-K0001193125-26-088232cik 0001672619
“To date, we have obtained the custom-manufactured starting materials for active pharmaceutical ingredients ("APIs") manufacture from Pharmaron and Hande Sciences and our good manufacturing practice ("GMP") APIs from Pharmaron.”
FILING10-K0001193125-26-088232cik 0001672619
“The drug product for the ELVN-001 program is manufactured at Latitude Pharmaceuticals Inc., Quotient Sciences, and CoreRx.”
FILING10-K0001193125-26-088232cik 0001672619
“For example, we use Pharmaron, located in China, to conduct preclinical studies and clinical trials and provide us with active pharmaceutical ingredients ("APIs").”
FILING10-K0001193125-26-088232cik 0001672619
“The drug product for the ELVN-001 program is manufactured at Latitude Pharmaceuticals Inc., Quotient Sciences, and CoreRx.”
FILING10-K0001193125-26-088232cik 0001672619
“On June 23, 2023, we entered into an Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which we may offer and sell shares of our common stock, from time to time, through an "at-the-market" program under the Securities Act.”
FILING10-K0001193125-26-088232cik 0001672619
Watchlist prices, news filtered to it, and its next report on your desk.
ELVN (Enliven Therapeutics, Inc.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JEF −2.47%, in financials.